Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact

​PD-1/PD-L1 Combination Strategies
Focus: Melanoma Indication
Image Credit: Ed Uthman
 
Note:
1. If you are viewing this webpage on mobile, please use Landscape mode for better visual and reading experience.
2. We are publishing here a part of the report. Write to us at support@oncofocus.com to receive the full report.  

Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally.

With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. 

With the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.

​​We had  three  specific objectives
Picture

We zeroed in on ​382 clinical trials
Picture

And identified 33 PD-1/PD-L1 inhibitors
20 PD-1 Inhibitors
1 Bi-specific PD-1/PD-L1 inhibitor
12 PD-L1 Inhibitors
Picture

We observed the following three major combination strategies:
 
- increasing tumor immunogenicity
- reversing tumor immunosuppression
- targeting other signaling pathways that promote growth & proliferation
Picture

Top three PD-1 combinations: CTLA4, Vaccines, and Radiation therapy​
Picture
Clinical Trial Intensity in Melanoma
File Size: 285 kb
File Type: png
Download File


Bringing everything together
To build upon the clinical gains observed with immunotherapeutic agents, several companies/organizations are actively researching combination of ICIs with different agents. With respect to PD-1/PD-L1,  there are about 400 clinical trials investigating 33 inhibitors either as monotherapy or in combination.

The combination of PD-1/PD-L1 targeting agents with CTLA4 targeting agents is the most common combination strategy. Redundancy? 

Picture
Are you seeking a comprehensive assessment of combination strategies and rationale behind each? Are you looking for an experienced research agency to decide which indication to prioritize for your preclinical/clinical assets? 

Oncofocus has years of experience in providing solutions across product lifecycle. Engage Us!

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact